COMPANY PROFILE

Huraypositive

Analyzes the health data of chronic patients and provides customized counseling protocols such as meals and nutrition, medications, and exercise to promote continuous health management

Seoul, South KoreaFounded 2010Health Tech & Medtech

Valuation $100–250M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Huraypositive

Huraypositive is a digital healthcare company focused on enhancing human life through innovative medical solutions. The company operates in the healthcare and biotechnology market, primarily serving medical institutions, laboratories, and healthcare providers. Huraypositive has secured global sales authorization for the COVID-19 Real Time PCR kit from Intron Biotechnology, which is a key product in their portfolio. This authorization allows them to distribute these kits worldwide, providing a critical tool in the fight against the COVID-19 pandemic. The business model is centered around the development, authorization, and distribution of advanced medical diagnostic tools. Revenue is generated through the sales of these diagnostic kits and other healthcare solutions. Huraypositive aims to add positive values to human life by leveraging digital healthcare technologies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2010
Headquarters: Seoul, South Korea
Employees: 52
Open positions: 1
Dealroom signal: 60.9/100
Industry: Health
Sub-industry: Health Platform
Sector: Health Tech & Medtech, DNA, Genetics and genomics, Hard Tech
Client focus: b2c
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES C✓Equity / VC	May 2022	$17M	$67M	Stonebridge · IMM Investment	—
SERIES B✓Equity / VC	Oct 2020	$13M	$50M	TimewiseInvestment · HGI Capital Group · Stonebridge · IMM Investment	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Huraypositive website traffic

Latest recorded traffic for Huraypositive is 49K monthly website visits, up 1714.8% over the last three months. Huraypositive's team declined 10.3% over the past year.

Latest monthly visits49K 3-month web change+1714.8% 1-year team growth-10.3%

Monthly website visitsDec 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational	11	$3.4M	$7M
AGAgeRateUtilizing predictive algorithms with multi-omic datasets to derive meaningful insights into your health and longevity. With a blood test we allow people to monitor their agerate and discover how they can alter their lifestyle habits to slow or reverse aging	Hamilton, Canada	Operational
RIRightangledAt-home DNA testing and online pharmacy services	London, United Kingdom	Operational
HUHurdleIs an AI driven platform unlocking the power of epigenetics for personalized healthcare	London, United Kingdom	Operational
MYMyHeritageLeading global discovery platform for exploring family history, uncovering ethnic origins, finding new relatives, and gaining health insights	Or Yehuda, Israel	Acquired
GEGenoPalateGenoPalate analyzes genetic data, demographics and lifestyle information to deliver personalized insights for optimal healthy eating	Milwaukee, United States	Operational
DNDnaNudgeDNA-based guidance for personalized shopping and health choices	London, United Kingdom	Operational
NGNebula GenomicsNebula Genomics leverages blockchain technology to eliminate middlemen and empower people to own their personal genomic data	Boston, United States	Operational